Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,340 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05940116 | A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 322 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05824325 | Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY） | active not recruiting | Phase 1 / Phase 2 | 56 | Fudan UniversityOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05911464 | A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 248 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04020575 | Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*) | recruiting | Phase 1 | 69 | Minerva Biotechnologies CorporationINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05909436 | Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors | recruiting | Phase 1 / Phase 2 | 107 | Guangzhou Gloria Biosciences Co., Ltd.INDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT02275286 | Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients(TRASTS) | recruiting | Phase 1 / Phase 2 | 199 | Grupo Espanol de Investigacion en SarcomasOTHER | 3 | May 31, 2023 | clinicaltrials |
| NCT05688488 | Clinical Study of Curcumin in Preventing Postoperative Adhesion of Bilateral Vocal Cords | recruiting | Phase 1 / Phase 2 | 100 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05842707 | Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 48 | Aibin Liang，MD，Ph.D.OTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05823285 | A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients | recruiting | Phase 1 | 150 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 21, 2023 | clinicaltrials |
| NCT04526834 | Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma(CERTAIN) | active not recruiting | Phase 1 | 21 | Tessa TherapeuticsINDUSTRY | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05271916 | First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations | recruiting | Phase 1 / Phase 2 | 140 | Shanghai Chest HospitalOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT04928222 | Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II) | active not recruiting | Phase 1 / Phase 2 | 25 | SkinJect, Inc.INDUSTRY | 1 | Apr 14, 2023 | clinicaltrials |
| NCT05361954 | Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors | not yet recruiting | Phase 1 | 36 | Sorrento Therapeutics, Inc.INDUSTRY | 0 | Apr 12, 2023 | clinicaltrials |
| NCT05804864 | A Study of KM501 in Patients With Solid Tumors | not yet recruiting | Phase 1 | 96 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 7, 2023 | clinicaltrials |
| NCT05204862 | Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 240 | TiumBio Co., Ltd.INDUSTRY | 2 | Apr 3, 2023 | clinicaltrials |
| NCT05352828 | Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy(ACTION) | active not recruiting | Phase 1 | 15 | Tessa TherapeuticsINDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT05521802 | A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 92 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT03544736 | Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC) | active not recruiting | Phase 1 / Phase 2 | 30 | Oslo University HospitalOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT05698238 | Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours(CAMP1) | not yet recruiting | Phase 1 | 50 | Mabpro, a.s.INDUSTRY | 0 | Mar 15, 2023 | clinicaltrials |
| NCT05766527 | A Study of KM602 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 38 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 13, 2023 | clinicaltrials |
| NCT05286320 | Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis. | not yet recruiting | Phase 1 / Phase 2 | 27 | National Taiwan University HospitalOTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT04499573 | Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL | active not recruiting | Phase 1 / Phase 2 | 50 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT04014530 | Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study(ATAPEMBRO) | recruiting | Phase 1 / Phase 2 | 47 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT05210270 | HYpofractionated Pelvic Radiotherapy for Advanced Cervical Cancers INeligible for ChemoTherapy(HYACINCT) | not yet recruiting | Phase 1 / Phase 2 | 55 | University of Santo Tomas Hospital, PhilippinesOTHER | 0 | Jan 31, 2023 | clinicaltrials |
| NCT05367700 | A Study of HS-10382 in Patients With Chronic Myeloid Leukemia. | recruiting | Phase 1 | 108 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 13, 2023 | clinicaltrials |
| NCT05682755 | Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT | recruiting | Phase 1 / Phase 2 | 77 | Sichuan UniversityOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT05659628 | CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL | recruiting | Phase 1 | 24 | Ningbo No. 1 HospitalOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT05627960 | First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies | recruiting | Phase 1 | 77 | A&G Pharmaceutical Inc.INDUSTRY | 1 | Nov 28, 2022 | clinicaltrials |
| NCT03064867 | Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 65 | Molly GalloglyOTHER | 1 | Nov 16, 2022 | clinicaltrials |
| NCT05590572 | A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma | not yet recruiting | Phase 1 / Phase 2 | 148 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 2 | Oct 21, 2022 | clinicaltrials |
| NCT05584761 | Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML | recruiting | Phase 1 / Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT05581875 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory | not yet recruiting | Phase 1 / Phase 2 | 48 | Hellenic Society of HematologyOTHER | 0 | Oct 17, 2022 | clinicaltrials |
| NCT05539118 | Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma | not yet recruiting | Phase 1 / Phase 2 | 48 | Xijing HospitalOTHER | 1 | Sep 14, 2022 | clinicaltrials |
| NCT05528055 | A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors | recruiting | Phase 1 | 122 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 6, 2022 | clinicaltrials |
| NCT05519670 | A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr(CAPRICE) | not yet recruiting | Phase 1 / Phase 2 | 72 | Institut Paoli-CalmettesOTHER | 0 | Aug 29, 2022 | clinicaltrials |
| NCT05506332 | Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 10 | University Hospital, AntwerpOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04214886 | CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies | active not recruiting | Phase 1 | 24 | Loyola UniversityOTHER | 1 | Aug 15, 2022 | clinicaltrials |
| NCT04502394 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | recruiting | Phase 1 / Phase 2 | 84 | Kartos Therapeutics, Inc.INDUSTRY | 11 | Aug 4, 2022 | clinicaltrials |
| NCT05366478 | A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 15 | Suzhou BlueHorse Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 2, 2022 | clinicaltrials |
| NCT05320588 | A Study in Patients With Advanced Cancers | recruiting | Phase 1 / Phase 2 | 332 | BiOneCure Therapeutics Inc.INDUSTRY | 1 | Jul 19, 2022 | clinicaltrials |
| NCT01744223 | Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 36 | Bellicum PharmaceuticalsINDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT02477878 | Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant | active not recruiting | Phase 1 | 10 | Bellicum PharmaceuticalsINDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT03301168 | Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 120 | Bellicum PharmaceuticalsINDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT05445011 | Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 12 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05445154 | SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | recruiting | Phase 1 / Phase 2 | 58 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05392699 | ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy | recruiting | Phase 1 | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT05338931 | Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | recruiting | Phase 1 / Phase 2 | 82 | AbClonINDUSTRY | 1 | May 26, 2022 | clinicaltrials |
| NCT03444844 | Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 60 | Five Eleven Pharma, Inc.INDUSTRY | 1 | May 2, 2022 | clinicaltrials |
| NCT05323201 | Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer | recruiting | Phase 1 / Phase 2 | 15 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Apr 12, 2022 | clinicaltrials |
| NCT05320874 | A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors. | not yet recruiting | Phase 1 | 232 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 11, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jul 12, 2023source: clinicaltrials